Ming Gao

Prof. Dr. Ming Gao


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ZYZhen Yang
Zhen Yang
HLHonglin Li
Honglin Li
JHJie Hao
Jie Hao
HMHanwei Mei
Hanwei Mei
MQMinghan Qiu
Minghan Qiu
MGMing Gao
Ming Gao
Pancreatic cancer (PC) has become a worldwide challenge attributed to its difficult early diagnosis and rapid progression. Treatments continue to be limited besides surgical resection. Hence, we aimed to discover novel biological signatures as clinically effective therapeutic targets for PC via the mining of public tumor databases. We found that epiphycan (EPYC) could function as an independent risk factor to predict the poor prognosis in PC based on integrated bioinformatics analysis. We downloaded associated PC data profiles from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) online websites, then applied the software Rstudio to filter out genes under the strict criteria. After the batch survival analysis using Log-rank test and univariate cox regression, we obtained 39 candidate genes. Subsequently, we narrowed the scope to 8 genes by establishing a Lasso regression model. Eventually, we focused on 2 genes (EPYC and MET) by further building a multivariate cox regression model. Given that the role of EPYC in PC remains obscure, we then performed a series of molecular functional experiments, including RT-qPCR, CCK8, EdU, colony formation, Transwell, western blot, cell live-dead staining, subcutaneous tumor formation, to enhance our insight into its underlying molecular mechanisms. The above results demonstrated that EPYC was highly expressed in PC cell lines and could promote the proliferation of PCs via PI3K-AKT signaling pathway in vivo and in vitro. We arrived at a conclusion that EPYC was expected to be a biological neo-biomarker for PC followed by being a potential therapeutic target.

15 September 2024 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
QSQi Sun
Qi Sun
ZYZhen Yang
Zhen Yang
MQMinghan Qiu
Minghan Qiu
SWShoujun Wang
Shoujun Wang
XZXingli Zhao
Xingli Zhao
MGMing Gao
Ming Gao

6 April 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
YGYing Gao
Ying Gao
JWJinmiao Wang
Jinmiao Wang
WTWeijie Tao
Weijie Tao
SWShoujun Wang
Shoujun Wang
HXHai Xie
Hai Xie
MGMing Gao
Ming Gao
Background Primary thyroid lymphoma (PTL) is a rare and aggressive malignancy with a need for more precise prognostication tools due to the limitations of existing staging systems. This study aims to develop a nomogram to predict overall survival (OS) rates in PTL patients, addressing the gap in personalized treatment protocols. Methods We analyzed 1469 PTL cases. Cox regression analyses were used to identify key prognostic factors and construct a survival prognostic nomogram. The nomogram’s performance was evaluated using receiver operating characteristic (ROC) curves and decision curve analysis. Additionally, a web-based dynamic nomogram was developed to estimate mortality risk for PTL patients. Results The nomogram exhibited high clinical utility and precision as determined by decision curve analysis and ROC curves. Furthermore, a novel risk stratification system was introduced. Kaplan–Meier survival curves illustrated significant differences among various risk groups, reinforcing the nomogram’s substantial clinical value in predicting OS for PTL patients (P < 0.0001). SHAP value analysis clarified each variable’s specific impact on the outcome. Conclusions The nomogram provides a valuable instrument for clinicians to individualize OS predictions for PTL patients, addressing the unmet need for personalized prognostication in this rare malignancy.

1 July 2025 in Gland Surgery
Verified
Journal Article
Open access
PDF file
YGYing Gao
Ying Gao
LLLei Liu
Lei Liu
SWShoujun Wang
Shoujun Wang
WTWeijie Tao
Weijie Tao
JWJinmiao Wang
Jinmiao Wang
MGMing Gao
Ming Gao
Background: Breast cancer (BC) is the leading cancer in women. It often metastasizes to bone, worsening the prognosis. Diagnostic methods often fail to predict bone metastasis (BM). This study developed a machine learning (ML) model using the Surveillance, Epidemiology, and End Results (SEER) database for BM prediction, to refine treatments and improve outcomes. Methods: Using SEER data, we studied 24,584 BC patients diagnosed 2010–2015 with radiologically confirmed BM. Tumor size, grade, tumor (T)/node (N) stages, and estrogen receptor (ER)/progesterone receptor (PR)/human epidermal growth factor receptor 2 (HER2) status were assessed. Stratified randomization divided the data into 70% training (n=18,438) and 30% validation (n=6,146). Six ML algorithms were developed, emphasizing random forest (RF). Receiver operating characteristic (ROC) curve analysis [area under the curve (AUC), sensitivity, specificity, negative predictive value (NPV)] assessed performance. The SHapley Additive exPlanations (SHAP) framework identified key BM predictors. Results: Our analysis of 24,584 patients identified 1,298 (5.26%) patients with BM. Logistic regression (LR) provided the highest specificity [0.897, 95% confidence interval (CI): 0.889–0.905], contrasting with gradient boosting machine (GBM)’s maximal sensitivity (0.658, 95% CI: 0.609–0.707). With sensitivity at 0.658, better algorithms or multimodal methods are needed for case identification. The multilayer perceptron neural network (MLPNN) model demonstrated superior performance, with the highest AUC of 0.808 (95% CI: 0.798–0.818), surpassing the LR and adaptive boosting (AdaBoost) models, both with AUCs of 0.803 (95% CI: 0.793–0.813). The RF model was particularly adept at ruling out BM, with an NPV above 97%. The SHAP analysis identified tumor size, grade, T/N stages, ER/PR/HER2 status, and brain/liver/lung metastases as key predictors for risk stratification. Decision curve analysis showed RF’s superior utility over the American Joint Committee on Cancer (AJCC) Staging System. Conclusions: Our ML model demonstrates potential for predicting BM in patients with BC. It may serve as a clinical aid to identify at-risk individuals early. However, moderate sensitivity requires refinement for better case detection. This study supports integrating ML into clinical practice, advancing personalized oncology medicine.

1 December 2024 in Gland Surgery
Verified
Journal Article
Open access
PDF file
YGYing Gao
Ying Gao
MTMengran Tian
Mengran Tian
XHXiukun Hou
Xiukun Hou
WHWeijing Hao
Weijing Hao
YZYanhui Zhang
Yanhui Zhang
DLDapeng Li
Dapeng Li
Background: Multifocality is a distinctive feature of papillary thyroid carcinoma (PTC); however, the biological behavior of PTC and its optimal management strategy remain unclear. The aim of this study was to analyze the clinical features and prognostic differences of multifocal papillary carcinoma and to guide the precise treatment of multifocal papillary carcinoma. Methods: The medical records of 1,139 patients with PTC who had undergone total or hemi-thyroidectomy between April and October 2013 at the Tianjin Medical University Cancer Institute and Hospital were reviewed. The number of central compartment lymph node metastasis (LNM), as well as the size, number, and laterality of each tumor focus, along with other possible risk factors were recorded. Patients were followed up until May 2024. Results: According to univariate and multivariable analyses, PTC, multifocality, and male sex were risk factors for level VI LNM. Moreover, the central compartment LNM rate increased proportionally with the number of foci. The LNM rates for patients with unilateral papillary thyroid microcarcinoma (PTMC) having one, two, three, and four foci were 27.8% (146/525), 37.3% (55/142), 40% (14/35), and 57.1% (4/7), respectively; conversely, the LNM rates for patients with bilateral PTC having two, three, four, five, and six foci were 50% (15/30), 62.5% (15/24), 70% (7/10), 83.3% (5/6), and 100% (2/2), respectively. Notably, the LNM rates were comparable for multifocal PTMCs (largest tumor diameter: 6–10 mm) and unilateral unifocal PTCs [44.0% (55/125) vs. 60.8% (59/97); P=0.43 (0.42–0.93)]. Meanwhile, the survival rates and risk of recurrence were comparable for multifocal and unifocal PTCs. Conclusions: Multifocality is indicative of a heightened risk of LNM in PTC but does not increase the risk of recurrence or mortality. Multifocal PTMCs with a tumor diameter of 6–10 mm should undergo thorough preoperative evaluation of the regional lymph nodes as they have a higher risk of developing LNM.

1 January 2023 in Open Medicine
Verified
Journal Article
Open access
PDF file
JHJie Hao
Jie Hao
SWShoujun Wang
Shoujun Wang
JWJinmiao Wang
Jinmiao Wang
ZZZhendong Zhang
Zhendong Zhang
MGMing Gao
Ming Gao
YWYajuan Wan
Yajuan Wan
This study aimed to explore the prognostic and predictive value of autophagy-related lncRNAs in papillary thyroid carcinoma (PTC). The expression data of autophagy-related genes and lncRNAs of the PTC patients were obtained from TCGA database. Autophagy-related-differentially expressed lncRNAs (DElncs) were identified and used to establish the lncRNAs signature predicting patients’ progression-free interval (PFI) in the training cohort. Its performance was assessed in the training cohort, validation cohort, and entire cohort. Effects of the signature on I-131 therapy were also explored. We identified 199 autophagy-related-DElncs and constructed a novel six-lncRNAs signature was constructed based on these lncRNAs. This signature had a good predictive performance and was superior to TNM stages and previous clinical risk scores. I-131 therapy was found to be associated with favorable prognosis in patients with high-risk scores but not those with low-risk scores. Gene set enrichment analysis suggested that a series of hallmark gene sets were enriched in the high-risk subgroup. Single-cell RNA sequencing analysis suggested that the lncRNAs were mainly expressed in thyroid cells but not stromal cells. In conclusion, our study constructed a well-performed six-lncRNAs signature to predict PFI and I-131 therapy benefits in PTC.